Preclinical characterization and clinical evaluation of tacrolimus eye drops
Severe allergic ocular diseases as atopic keratoconjunctivitis can induce corneal damage due to inflammatory substances released from giant papillae. Tacrolimus eye drops are one of the current therapeutic alternatives for its treatment. This work is aimed at developing and characterizing a 0.03% ta...
Saved in:
Published in | European journal of pharmaceutical sciences Vol. 120; pp. 152 - 161 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
30.07.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Severe allergic ocular diseases as atopic keratoconjunctivitis can induce corneal damage due to inflammatory substances released from giant papillae. Tacrolimus eye drops are one of the current therapeutic alternatives for its treatment. This work is aimed at developing and characterizing a 0.03% tacrolimus ophthalmic formulation, which was introduced in three types of vehicles (BBS, PVA and Hyaluronic Acid). For this, we have performed in vitro (stability studies) and in vivo assays (corneal permanence time measured directly by Positron Emission Tomography) of three potential formulations. Next, the best formulation was selected, and its toxicological profile and clinical effectiveness have been evaluated. The biopermanence studies (direct measurements and PET/CT) showed that the formulations with PVA and Hyaluronic Acid present more retention time on the ocular surface of rats than PBS. From the stability study, we have determined that tacrolimus with PVA in cold storage is the best option. Tacrolimus with PVA has shown lower cytotoxicity than cyclosporine at early times. On the other hand, the pilot study performed has shown significant improvements in patients, with no noticeable adverse reactions. Based on stability, biopermanence, safety and clinical effectiveness studies, we concluded that tacrolimus-PVA eye drops are a suitable candidate for its clinical application in inflammatory ophthalmology diseases.
[Display omitted] |
---|---|
AbstractList | Severe allergic ocular diseases as atopic keratoconjunctivitis can induce corneal damage due to inflammatory substances released from giant papillae. Tacrolimus eye drops are one of the current therapeutic alternatives for its treatment. This work is aimed at developing and characterizing a 0.03% tacrolimus ophthalmic formulation, which was introduced in three types of vehicles (BBS, PVA and Hyaluronic Acid). For this, we have performed in vitro (stability studies) and in vivo assays (corneal permanence time measured directly by Positron Emission Tomography) of three potential formulations. Next, the best formulation was selected, and its toxicological profile and clinical effectiveness have been evaluated. The biopermanence studies (direct measurements and PET/CT) showed that the formulations with PVA and Hyaluronic Acid present more retention time on the ocular surface of rats than PBS. From the stability study, we have determined that tacrolimus with PVA in cold storage is the best option. Tacrolimus with PVA has shown lower cytotoxicity than cyclosporine at early times. On the other hand, the pilot study performed has shown significant improvements in patients, with no noticeable adverse reactions. Based on stability, biopermanence, safety and clinical effectiveness studies, we concluded that tacrolimus-PVA eye drops are a suitable candidate for its clinical application in inflammatory ophthalmology diseases. Severe allergic ocular diseases as atopic keratoconjunctivitis can induce corneal damage due to inflammatory substances released from giant papillae. Tacrolimus eye drops are one of the current therapeutic alternatives for its treatment. This work is aimed at developing and characterizing a 0.03% tacrolimus ophthalmic formulation, which was introduced in three types of vehicles (BBS, PVA and Hyaluronic Acid). For this, we have performed in vitro (stability studies) and in vivo assays (corneal permanence time measured directly by Positron Emission Tomography) of three potential formulations. Next, the best formulation was selected, and its toxicological profile and clinical effectiveness have been evaluated. The biopermanence studies (direct measurements and PET/CT) showed that the formulations with PVA and Hyaluronic Acid present more retention time on the ocular surface of rats than PBS. From the stability study, we have determined that tacrolimus with PVA in cold storage is the best option. Tacrolimus with PVA has shown lower cytotoxicity than cyclosporine at early times. On the other hand, the pilot study performed has shown significant improvements in patients, with no noticeable adverse reactions. Based on stability, biopermanence, safety and clinical effectiveness studies, we concluded that tacrolimus-PVA eye drops are a suitable candidate for its clinical application in inflammatory ophthalmology diseases. [Display omitted] |
Author | Fernández-Ferreiro, Anxo Rodríguez-Ares, María Teresa García-Otero, Xurxo González-Barcia, Miguel Lamas, María Jesús Touriño-Peralba, Rosario Aguiar, Pablo Martínez-Pérez, Laura Silva-Rodríguez, Jesús Otero-Espinar, Francisco J. Gómez-Lado, Noemí Alonso-Rodríguez, Iria Luaces-Rodríguez, Andrea Herranz, Michel Ruibal-Morell, Álvaro |
Author_xml | – sequence: 1 givenname: Andrea surname: Luaces-Rodríguez fullname: Luaces-Rodríguez, Andrea organization: Department of Pharmacology, Pharmacy and Pharmaceutical Technology and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain – sequence: 2 givenname: Rosario surname: Touriño-Peralba fullname: Touriño-Peralba, Rosario organization: Ophthalmology Department, University Clinical Hospital Santiago de Compostela (SERGAS), Santiago de Compostela, Spain – sequence: 3 givenname: Iria surname: Alonso-Rodríguez fullname: Alonso-Rodríguez, Iria organization: Department of Pharmacology, Pharmacy and Pharmaceutical Technology and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain – sequence: 4 givenname: Xurxo surname: García-Otero fullname: García-Otero, Xurxo organization: Department of Pharmacology, Pharmacy and Pharmaceutical Technology and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain – sequence: 5 givenname: Miguel surname: González-Barcia fullname: González-Barcia, Miguel organization: Department of Pharmacology, Pharmacy and Pharmaceutical Technology and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain – sequence: 6 givenname: María Teresa surname: Rodríguez-Ares fullname: Rodríguez-Ares, María Teresa organization: Ophthalmology Department, University Clinical Hospital Santiago de Compostela (SERGAS), Santiago de Compostela, Spain – sequence: 7 givenname: Laura surname: Martínez-Pérez fullname: Martínez-Pérez, Laura organization: Ophthalmology Department, University Clinical Hospital Santiago de Compostela (SERGAS), Santiago de Compostela, Spain – sequence: 8 givenname: Pablo surname: Aguiar fullname: Aguiar, Pablo organization: Molecular Imaging Group, University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain – sequence: 9 givenname: Noemí surname: Gómez-Lado fullname: Gómez-Lado, Noemí organization: Molecular Imaging Group, University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain – sequence: 10 givenname: Jesús surname: Silva-Rodríguez fullname: Silva-Rodríguez, Jesús organization: Molecular Imaging Group, University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain – sequence: 11 givenname: Michel surname: Herranz fullname: Herranz, Michel organization: Molecular Imaging Group, University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain – sequence: 12 givenname: Álvaro surname: Ruibal-Morell fullname: Ruibal-Morell, Álvaro organization: Molecular Imaging Group, University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain – sequence: 13 givenname: María Jesús surname: Lamas fullname: Lamas, María Jesús organization: Clinical Pharmacology Group, University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain – sequence: 14 givenname: Francisco J. surname: Otero-Espinar fullname: Otero-Espinar, Francisco J. email: francisco.otero@usc.es organization: Department of Pharmacology, Pharmacy and Pharmaceutical Technology and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain – sequence: 15 givenname: Anxo orcidid: 0000-0002-7348-7337 surname: Fernández-Ferreiro fullname: Fernández-Ferreiro, Anxo email: anxordes@gmail.com organization: Department of Pharmacology, Pharmacy and Pharmaceutical Technology and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29705214$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kE1LxDAQhoOsuB_6BzxI_0DrJE2TFLzI4hcs6EHPIU2mmNJtl6S7sP56u1Q9ehqYeZ-X4VmSWdd3SMg1hYwCFbdNhs0uZgyoyoBnkKszsqBKlilIBjOygJKpFEol52QZYwMAQkm4IHNWSigY5QuyeQtoW995a9rEfppg7IDBf5nB911iOpf8XfFg2v207-tkMDb0rd_uY4JHTFzod_GSnNemjXj1M1fk4_Hhff2cbl6fXtb3m9TmhRjSvMyNsIZzLpkRtGIuz1VBoRZ1aXKLlFZKopIKnAXHC2G4wKpStsaRKWi-ImzqHV-IMWCtd8FvTThqCvqkRjf6pEaf1GjgelQzQjcTtNtXW3R_yK-LMXA3BXB8_eAx6Gg9dhadHx0N2vX-v_5vqqJ37w |
CitedBy_id | crossref_primary_10_1167_tvst_11_8_20 crossref_primary_10_3390_ijms241612615 crossref_primary_10_2147_OPTH_S229405 crossref_primary_10_3390_pharmaceutics13101737 crossref_primary_10_1080_10717544_2023_2175925 crossref_primary_10_3390_pharmaceutics12080717 crossref_primary_10_1016_j_ijpharm_2018_11_022 crossref_primary_10_1016_j_jddst_2022_103945 crossref_primary_10_3390_pharmaceutics11050237 crossref_primary_10_1007_s11440_023_01997_z crossref_primary_10_1016_j_ijpharm_2021_120364 crossref_primary_10_3390_pharmaceutics13020149 crossref_primary_10_12677_HJO_2022_113031 crossref_primary_10_3390_pharmaceutics12060570 crossref_primary_10_1016_j_jhydrol_2022_127806 crossref_primary_10_3390_pharmaceutics14040799 crossref_primary_10_1016_j_ijpharm_2024_124192 |
Cites_doi | 10.1016/j.ejpb.2017.03.006 10.1016/0092-8674(91)90124-H 10.1016/S0304-3959(01)00314-1 10.1016/S0002-9394(14)73645-1 10.1167/iovs.07-0229 10.1007/s11882-013-0345-0 10.2146/ajhp160169 10.1016/S0002-9394(14)72551-6 10.1007/s11745-997-0069-1 10.1097/ICO.0000000000001200 10.5935/0034-7280.20160087 10.1016/j.fct.2011.11.040 10.1097/ICO.0b013e31823f8c9b 10.1016/S0161-6420(01)00759-X 10.1001/archderm.135.5.574 10.1016/j.colsurfb.2016.01.014 10.1097/ICO.0b013e31820cd607 10.2147/OPTH.S101627 10.1016/j.jaci.2004.01.077 10.2332/allergolint.11-OA-0349 10.1023/A:1011956327987 10.3109/02713683.2015.1082187 10.1016/j.drudis.2013.10.001 10.1038/eye.2011.75 10.1016/j.ophtha.2015.10.011 10.1016/S0168-3659(98)00150-3 10.1111/j.1442-9071.2008.01803.x 10.1016/j.addr.2010.09.015 10.1023/A:1015813225804 10.5935/0004-2749.20150078 10.4103/0974-9233.164616 10.1097/00003226-199207000-00003 10.1016/j.ijpharm.2017.06.060 10.1080/02713680802149115 10.1080/17425255.2016.1209481 10.5497/wjp.v2.i2.47 10.1136/bjo.2006.097428 10.1016/j.jfo.2012.03.019 10.1089/jop.2009.0087 10.1016/j.ijpharm.2015.09.058 10.1002/acr.20543 10.1016/S0939-6411(96)00010-0 10.1136/bjophthalmol-2013-304453 10.1089/jop.2008.0125 10.1007/s00417-001-0424-0 10.1016/j.tiv.2005.12.008 10.1167/iovs.15-16444 10.1089/jop.2011.0108 10.1016/j.snb.2006.10.024 10.4103/2231-4040.85540 10.1016/j.cmpb.2010.01.007 10.1177/1087057105279635 10.1038/sj.eye.6700675 10.1136/bjo.2007.121533 10.1167/iovs.13-11717 10.1186/s40662-017-0072-z 10.2174/1566524015666150731095426 10.2147/OPTH.S99157 10.1136/bjophthalmol-2013-303639 |
ContentType | Journal Article |
Copyright | 2018 Elsevier B.V. Copyright © 2018 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: 2018 Elsevier B.V. – notice: Copyright © 2018 Elsevier B.V. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1016/j.ejps.2018.04.038 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1879-0720 |
EndPage | 161 |
ExternalDocumentID | 10_1016_j_ejps_2018_04_038 29705214 S0928098718302033 |
Genre | Journal Article Comparative Study Observational Study |
GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 53G 5GY 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AATCM AAXUO ABFRF ABJNI ABLJU ABMAC ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA GROUPED_DOAJ IHE J1W KOM M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SCC SDF SDG SDP SES SPCBC SSP SSZ T5K TEORI ~G- AAQFI AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM 0SF 29G 5VS AAQXK AAYXX ABFNM ABXDB ADMUD ADVLN ASPBG AVWKF AZFZN CITATION FEDTE FGOYB G-2 HMT HVGLF HZ~ OK1 R2- SEW SPT WUQ |
ID | FETCH-LOGICAL-c356t-393a6ca44472a61b2d338510f6f9a3ce11b87e8780dc0d456a46ebb8cfe444513 |
IEDL.DBID | .~1 |
ISSN | 0928-0987 |
IngestDate | Thu Sep 26 17:25:23 EDT 2024 Sat Sep 28 08:49:42 EDT 2024 Fri Feb 23 02:49:08 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Cytotoxicity Eye drops Effectiveness Stability Tacrolimus Corneal residence time |
Language | English |
License | Copyright © 2018 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c356t-393a6ca44472a61b2d338510f6f9a3ce11b87e8780dc0d456a46ebb8cfe444513 |
ORCID | 0000-0002-7348-7337 |
PMID | 29705214 |
PageCount | 10 |
ParticipantIDs | crossref_primary_10_1016_j_ejps_2018_04_038 pubmed_primary_29705214 elsevier_sciencedirect_doi_10_1016_j_ejps_2018_04_038 |
PublicationCentury | 2000 |
PublicationDate | 2018-07-30 |
PublicationDateYYYYMMDD | 2018-07-30 |
PublicationDate_xml | – month: 07 year: 2018 text: 2018-07-30 day: 30 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | European journal of pharmaceutical sciences |
PublicationTitleAlternate | Eur J Pharm Sci |
PublicationYear | 2018 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Dumrongkigchaiporn, Kosrirukvongs, Tantimongkolsuk, Jirapongsananuruk, Visitsunthorn, Vichyanond (bb0065) 2004; 113 (bb0355) 2017 Ruzicka, Assmann, Homey (bb0285) 1999; 135 Ishioka, Ohno, Nakamura, Isobe, Watanabe, Ishigatsubo, Tanaka (bb0150) 1994; 118 Thompson, Thompson, Young, Lin, Sanislo, Moshfeghi, Singh (bb0330) 2015; 56 Snibson, Greaves, Soper, Tiffany, Wilson, Bron (bb0315) 1992; 11 Ghasemi (bb0115) 2017; 0 Fernández-Ferreiro, González-Barcia, Gil-Martínez, Santiago Varela, Pardo, Blanco-Méndez, Piñeiro-Ces, Lamas Díaz, Otero-Espinar (bb0095) 2016; 40 Mochizuki, Masuda, Sakane, Ito, Kogure, Sugino, Usui, Mizushima, Ohno, Inaba (bb0205) 1993; 115 (accessed 8.17.17). Zanjani, Aminifard, Ghafourian, Pourazizi, Maleki, Arish, Shahrakipoor, Rohani, Abrishami, Khafri Zare, Barzegar Jalali (bb0385) 2017; 36 Fernández-Ferreiro, Silva-Rodríguez, Otero-Espinar, González-Barcia, Lamas, Ruibal, Luaces-Rodriguez, Vieites-Prado, Sobrino, Herranz, García-Varela, Blanco-Mendez, Gil-Martínez, Pardo, Moscoso, Medín-Aguerre, Pardo-Montero, Aguiar (bb0100) 2017; 58 International Conference on Harmonisation (ICH) (bb0145) 1996 Saarinen-Savolainen, Järvinen, Araki-Sasaki, Watanabe, Urtti (bb0290) 1998; 15 Pleyer, Lutz, Jusko, Nguyen, Narawane, Rückert, Mondino, Lee, Nguyen (bb0270) 1993; 34 Gomes, Abrunhosa, Ramos, Pauwels (bb0120) 2011; 63 Attas-Fox, Barkana, Iskhakov, Rayvich, Gerber, Morad, Avni, Zadok (bb0020) 2008; 33 Mochizuki, Yamada, Hato, Nishida (bb0210) 2008; 92 de Paulis, Cirillo, Ciccarelli, Condorelli, Marone (bb0255) 1991; 1950 Hawker, Mian, Kendzerska, French (bb0135) 2011; 63 Patel, Cholkar, Agrahari, Mitra (bb0250) 2013; 2 Magalhaes, Marinho, Kwitko (bb0200) 2013; 97 Egwuagu, Sun, Kim, Dambuza (bb0075) 2015; 15 Ribeiro, Ribeiro, Ribeiro, Ferreira, Barbosa, Ribeiro, Ribeiro, Ribeiro, Ferreira, Barbosa (bb0275) 2016; 75 Oh, Yu, Ko (bb0230) 2013; 54 Ezquer-Garin, Ferriols-Lisart, Alós-Almiñana (bb0080) 2017; 74 Moscovici, Holzchuh, Chiacchio, Santo, Shimazaki, Hida (bb0215) 2012; 31 Bielory, Bielory (bb0030) 2016 Jeng, Holsclaw (bb0155) 2011; 30 The Association for Research in Vision and Ophthalmology (bb0325) 2014 Zhang, Huo, Zhou, Xie (bb0395) 2010; 99 Kawazu, Yamada, Nakamura, Ota (bb0165) 1999; 40 [WWW Document], (2014) URL Fernández-Ferreiro, Santiago-Varela, Gil-Martínez, Parada, Pardo, González-Barcia, Piñeiro-Ces, Rodríguez-Ares, Blanco-Mendez, Lamas, Otero-Espinar (bb0085) 2015; 495 Wu, Jacobson, Berzon, Revicki, van der Horst, Fichtenbaum, Saag, Lynn, Hardy, Feinberg (bb0360) 1997; 6 Bonini, Coassin, Aronni, Lambiase (bb0035) 2004; 18 Xing, Zhu, Gabos, Xie (bb0365) 2006; 20 Luaces-Rodríguez, Díaz-Tomé, González-Barcia, Silva-Rodríguez, Herranz, Gil-Martínez, Rodríguez-Ares, García-Mazás, Blanco-Mendez, Lamas, Otero-Espinar, Fernández-Ferreiro (bb0195) 2017; 528 Lienert, Tarko, Uchino, Christen, Schaumberg (bb0185) 2016; 123 Hicks, von Baeyer, Spafford, van Korlaar, Goodenough (bb0140) 2001; 93 Stonecipher, Torkildsen, Ousler, Morris, Villanueva, Hollander (bb0320) 2016; 10 Atienza, Zhu, Wang, Xu, Abassi (bb0015) 2005; 10 Shoughy (bb0300) 2017; 4 Ceriotti, Ponti, Broggi, Kob, Drechsler, Thedinga, Colpo, Sabbioni, Ehret, Rossi (bb0045) 2007; 123 Fernández-Ferreiro, Santiago-Varela, Gil-Martínez, Parada, Pardo, González-Barcia, Piñeiro-Ces, Rodríguez-Ares, Blanco-Mendez, Lamas, Otero-Espinar (bb0090) 2015; 495 Uno, Yamaguchi, Li, Suzuki, Hashimoto, Harada, Kimura, Kazui (bb0335) 1997; 32 Ayaki, Yaguchi, Iwasawa, Koide (bb0025) 2008; 36 National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals (bb0220) 2011 Ebihara, Ohashi, Fujishima, Fukushima, Nakagawa, Namba, Okamoto, Shoji, Takamura, Uchio, Miyazaki (bb0070) 2012; 61 Davies, Farr, Hadgraft, Kellaway (bb0060) 1991; 8 Kheirkhah, Zavareh, Farzbod, Mahbod, Behrouz (bb0170) 2011; 25 Fukushima, Ohashi, Ebihara, Uchio, Okamoto, Kumagai, Shoji, Takamura, Nakagawa, Namba, Fujishima, Miyazaki (bb0105) 2014; 98 Ohashi, Ebihara, Fujishima, Fukushima, Kumagai, Nakagawa, Namba, Okamoto, Shoji, Takamura, Hayashi (bb0235) 2010; 26 Lallemand, Schmitt, Bourges, Gurny, Benita, Garrigue (bb0180) 2017; 117 Pastor-Clerigues, Serrano, Milara, Marti-Bonmati, Lopez-Perez, Garcia-Montanes, Sanfeliu, Saval-Victoria, Cortijo (bb0245) 2016; 41 Sloper, Powell, Dua (bb0310) 2001; 108 Said, Dutot, Christon, Beaudeux, Martin, Warnet, Rat (bb0295) 2007; 48 Joseph, Raj, Shanmuganathan, Powell, Dua (bb0160) 2007; 91 Christensen, McDonnell, Singh (bb0055) 2017 Liu, Farmer, Lane, Friedman, Weissman, Schreiber (bb0190) 1991; 66 Al-Amri, Mirza, Al-Hakami (bb0005) 2016; 23 Parrilha, Nai, Giuffrida, Barbero, Padovani, Pereira, Silva, Silva, Diniz, Andrade, Parrilha, Nai, Giuffrida, Barbero, Padovani, Pereira, Silva, Silva, Diniz, Andrade (bb0240) 2015; 78 Kumar, Karki, Meena, Prakash, Rajeswari, Goli (bb0175) 2011; 2 Chen, Cui, Jiang, Pang, Tang, Hou, Jiang, Hu (bb0050) 2012; 50 Wakamatsu, Tanaka, Satake, Dogru, Fukagawa, Igarashi, Fujishima (bb0345) 2011; 17 Zeng, Li, Wan, Liu, Pan, Wu, Zhang, Pan, Qin, Lin, Wu, Xu (bb0390) 2016; 141 Nishino, Fukushima, Okamoto, Ohashi, Fukata, Ozaki, Ueno (bb0225) 2002; 240 Almeida, Amaral, Lobão, Lobo (bb0010) 2014; 19 Greiner, Dick (bb0125) 2016 Yura, Yoshimura, Hamashima, Akamatsu, Nishikawa, Takakura, Hashida (bb0380) 1999; 57 Bonniard, Yeung, Chan, Birt (bb0040) 2016; 12 Vichyanond, Kosrirukvongs (bb0340) 2013; 13 Wan, Tang, Ye (bb0350) 2010; 45 Shoughy, Jaroudi, Tabbara (bb0305) 2016; 10 Hajiahmadi, Derkhshan, Nikandish, Malaekeh-Nikouei (bb0130) 2017; 24 Yuan, Zhai, Huang, Zhou, Chen (bb0375) 2012; 28 Gauthier, Rival, Sahler, Fagnoni-Legat, Limat, Guillaume, Delbosc (bb0110) 2013; 36 Royal Pharmaceutical Society of Great Britain Dept of Pharmaceutical (bb0280) 1994 Peppas, Mongia (bb0260) 1997; 43 Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis - Full Text View - Yuan, Zhai, Chen, Ye, Zhou (bb0370) 2009; 25 Shoughy (10.1016/j.ejps.2018.04.038_bb0305) 2016; 10 Ruzicka (10.1016/j.ejps.2018.04.038_bb0285) 1999; 135 Bonniard (10.1016/j.ejps.2018.04.038_bb0040) 2016; 12 Ghasemi (10.1016/j.ejps.2018.04.038_bb0115) 2017; 0 Hawker (10.1016/j.ejps.2018.04.038_bb0135) 2011; 63 Kawazu (10.1016/j.ejps.2018.04.038_bb0165) 1999; 40 Lienert (10.1016/j.ejps.2018.04.038_bb0185) 2016; 123 Fernández-Ferreiro (10.1016/j.ejps.2018.04.038_bb0090) 2015; 495 Greiner (10.1016/j.ejps.2018.04.038_bb0125) 2016 Patel (10.1016/j.ejps.2018.04.038_bb0250) 2013; 2 Uno (10.1016/j.ejps.2018.04.038_bb0335) 1997; 32 Zanjani (10.1016/j.ejps.2018.04.038_bb0385) 2017; 36 Ebihara (10.1016/j.ejps.2018.04.038_bb0070) 2012; 61 Pleyer (10.1016/j.ejps.2018.04.038_bb0270) 1993; 34 Egwuagu (10.1016/j.ejps.2018.04.038_bb0075) 2015; 15 Fernández-Ferreiro (10.1016/j.ejps.2018.04.038_bb0085) 2015; 495 Kumar (10.1016/j.ejps.2018.04.038_bb0175) 2011; 2 Zeng (10.1016/j.ejps.2018.04.038_bb0390) 2016; 141 Magalhaes (10.1016/j.ejps.2018.04.038_bb0200) 2013; 97 Pastor-Clerigues (10.1016/j.ejps.2018.04.038_bb0245) 2016; 41 Ohashi (10.1016/j.ejps.2018.04.038_bb0235) 2010; 26 Parrilha (10.1016/j.ejps.2018.04.038_bb0240) 2015; 78 Gauthier (10.1016/j.ejps.2018.04.038_bb0110) 2013; 36 International Conference on Harmonisation (ICH) (10.1016/j.ejps.2018.04.038_bb0145) Ishioka (10.1016/j.ejps.2018.04.038_bb0150) 1994; 118 Said (10.1016/j.ejps.2018.04.038_bb0295) 2007; 48 10.1016/j.ejps.2018.04.038_bb0265 Joseph (10.1016/j.ejps.2018.04.038_bb0160) 2007; 91 Peppas (10.1016/j.ejps.2018.04.038_bb0260) 1997; 43 Vichyanond (10.1016/j.ejps.2018.04.038_bb0340) 2013; 13 Yuan (10.1016/j.ejps.2018.04.038_bb0370) 2009; 25 Gomes (10.1016/j.ejps.2018.04.038_bb0120) 2011; 63 Fernández-Ferreiro (10.1016/j.ejps.2018.04.038_bb0100) 2017; 58 Moscovici (10.1016/j.ejps.2018.04.038_bb0215) 2012; 31 Shoughy (10.1016/j.ejps.2018.04.038_bb0300) 2017; 4 Hicks (10.1016/j.ejps.2018.04.038_bb0140) 2001; 93 Wu (10.1016/j.ejps.2018.04.038_bb0360) 1997; 6 Al-Amri (10.1016/j.ejps.2018.04.038_bb0005) 2016; 23 Stonecipher (10.1016/j.ejps.2018.04.038_bb0320) 2016; 10 Snibson (10.1016/j.ejps.2018.04.038_bb0315) 1992; 11 Dumrongkigchaiporn (10.1016/j.ejps.2018.04.038_bb0065) 2004; 113 Fernández-Ferreiro (10.1016/j.ejps.2018.04.038_bb0095) 2016; 40 Yura (10.1016/j.ejps.2018.04.038_bb0380) 1999; 57 Oh (10.1016/j.ejps.2018.04.038_bb0230) 2013; 54 Mochizuki (10.1016/j.ejps.2018.04.038_bb0205) 1993; 115 Ceriotti (10.1016/j.ejps.2018.04.038_bb0045) 2007; 123 Bielory (10.1016/j.ejps.2018.04.038_bb0030) 2016 Bonini (10.1016/j.ejps.2018.04.038_bb0035) 2004; 18 Chen (10.1016/j.ejps.2018.04.038_bb0050) 2012; 50 Thompson (10.1016/j.ejps.2018.04.038_bb0330) 2015; 56 Yuan (10.1016/j.ejps.2018.04.038_bb0375) 2012; 28 Attas-Fox (10.1016/j.ejps.2018.04.038_bb0020) 2008; 33 Jeng (10.1016/j.ejps.2018.04.038_bb0155) 2011; 30 Luaces-Rodríguez (10.1016/j.ejps.2018.04.038_bb0195) 2017; 528 Davies (10.1016/j.ejps.2018.04.038_bb0060) 1991; 8 Saarinen-Savolainen (10.1016/j.ejps.2018.04.038_bb0290) 1998; 15 The Association for Research in Vision and Ophthalmology (10.1016/j.ejps.2018.04.038_bb0325) Sloper (10.1016/j.ejps.2018.04.038_bb0310) 2001; 108 de Paulis (10.1016/j.ejps.2018.04.038_bb0255) 1991; 1950 Almeida (10.1016/j.ejps.2018.04.038_bb0010) 2014; 19 Wakamatsu (10.1016/j.ejps.2018.04.038_bb0345) 2011; 17 (10.1016/j.ejps.2018.04.038_bb0355) 2017 Ribeiro (10.1016/j.ejps.2018.04.038_bb0275) 2016; 75 National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals (10.1016/j.ejps.2018.04.038_bb0220) 2011 Fukushima (10.1016/j.ejps.2018.04.038_bb0105) 2014; 98 Xing (10.1016/j.ejps.2018.04.038_bb0365) 2006; 20 Liu (10.1016/j.ejps.2018.04.038_bb0190) 1991; 66 Ezquer-Garin (10.1016/j.ejps.2018.04.038_bb0080) 2017; 74 Hajiahmadi (10.1016/j.ejps.2018.04.038_bb0130) 2017; 24 Lallemand (10.1016/j.ejps.2018.04.038_bb0180) 2017; 117 Wan (10.1016/j.ejps.2018.04.038_bb0350) 2010; 45 Nishino (10.1016/j.ejps.2018.04.038_bb0225) 2002; 240 Mochizuki (10.1016/j.ejps.2018.04.038_bb0210) 2008; 92 Zhang (10.1016/j.ejps.2018.04.038_bb0395) 2010; 99 Christensen (10.1016/j.ejps.2018.04.038_bb0055) 2017 Ayaki (10.1016/j.ejps.2018.04.038_bb0025) 2008; 36 Kheirkhah (10.1016/j.ejps.2018.04.038_bb0170) 2011; 25 Atienza (10.1016/j.ejps.2018.04.038_bb0015) 2005; 10 Royal Pharmaceutical Society of Great Britain Dept of Pharmaceutical (10.1016/j.ejps.2018.04.038_bb0280) 1994 |
References_xml | – year: 2014 ident: bb0325 article-title: Statement for the Use of Animals in Ophthalmic and Visual Research [WWW Document] contributor: fullname: The Association for Research in Vision and Ophthalmology – volume: 93 start-page: 173 year: 2001 end-page: 183 ident: bb0140 article-title: The faces pain scale – revised: toward a common metric in pediatric pain measurement publication-title: Pain contributor: fullname: Goodenough – volume: 24 start-page: 19 year: 2017 end-page: 27 ident: bb0130 article-title: Preparation of tacrolimus ophthalmic solution using cyclodextrins publication-title: J. Birjand Univ. Med. Sci. contributor: fullname: Malaekeh-Nikouei – volume: 495 start-page: 680 year: 2015 end-page: 691 ident: bb0090 article-title: Ocular safety comparison of non-steroidal anti-inflammatory eye drops used in pseudophakic cystoid macular edema prevention publication-title: Int. J. Pharm. contributor: fullname: Otero-Espinar – volume: 17 start-page: 932 year: 2011 end-page: 938 ident: bb0345 article-title: Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis publication-title: Mol. Vis. contributor: fullname: Fujishima – volume: 36 start-page: 675 year: 2017 end-page: 678 ident: bb0385 article-title: Comparative evaluation of Tacrolimus versus interferon alpha-2b eye drops in the treatment of vernal Keratoconjunctivitis: a randomized, double-masked study publication-title: Cornea contributor: fullname: Barzegar Jalali – volume: 8 start-page: 1039 year: 1991 end-page: 1043 ident: bb0060 article-title: Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions publication-title: Pharm. Res. contributor: fullname: Kellaway – volume: 10 start-page: 887 year: 2016 end-page: 895 ident: bb0320 article-title: The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye publication-title: Clin. Ophthalmol. Auckl. NZ contributor: fullname: Hollander – volume: 25 start-page: 345 year: 2009 end-page: 350 ident: bb0370 article-title: Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration publication-title: J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther. contributor: fullname: Zhou – volume: 108 start-page: 1838 year: 2001 end-page: 1844 ident: bb0310 article-title: Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts publication-title: Ophthalmology contributor: fullname: Dua – volume: 56 start-page: 4324 year: 2015 ident: bb0330 article-title: Barriers to follow-up and strategies to improve adherence to appointments for care of chronic eye diseases publication-title: Investig. Opthalmology Vis. Sci. contributor: fullname: Singh – volume: 15 start-page: 517 year: 2015 end-page: 528 ident: bb0075 article-title: Ocular inflammatory diseases: molecular pathogenesis and immunotherapy publication-title: Curr. Mol. Med. contributor: fullname: Dambuza – volume: 36 start-page: 553 year: 2008 end-page: 559 ident: bb0025 article-title: Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells publication-title: Clin. Exp. Ophthalmol. contributor: fullname: Koide – volume: 113 start-page: S178 year: 2004 ident: bb0065 article-title: Vernal keratoconjunctivitis publication-title: J. Allergy Clin. Immunol. contributor: fullname: Vichyanond – volume: 0 start-page: 1 year: 2017 end-page: 14 ident: bb0115 article-title: Roles of IL-6 in ocular inflammation: a review publication-title: Ocul. Immunol. Inflamm. contributor: fullname: Ghasemi – volume: 45 start-page: 221 year: 2010 end-page: 223 ident: bb0350 article-title: Determination of tacrolimus ophthalmic emulsion by HPLC publication-title: J. Chin. Pharm. Sci. contributor: fullname: Ye – volume: 99 start-page: 306 year: 2010 end-page: 314 ident: bb0395 article-title: PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft excel publication-title: Comput. Methods Prog. Biomed. contributor: fullname: Xie – volume: 12 start-page: 1279 year: 2016 end-page: 1289 ident: bb0040 article-title: Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK) publication-title: Expert Opin. Drug Metab. Toxicol. contributor: fullname: Birt – volume: 33 start-page: 545 year: 2008 end-page: 549 ident: bb0020 article-title: Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study publication-title: Curr. Eye Res. contributor: fullname: Zadok – volume: 41 start-page: 890 year: 2016 end-page: 896 ident: bb0245 article-title: Evaluation of the ocular tolerance of three Tacrolimus topical pharmaceutical preparations by bovine corneal opacity and permeability test publication-title: Curr. Eye Res. contributor: fullname: Cortijo – start-page: 51 year: 2017 end-page: 78 ident: bb0055 article-title: Ocular manifestations of allergic and immunologic diseases publication-title: SpringerLink contributor: fullname: Singh – volume: 32 start-page: 543 year: 1997 end-page: 548 ident: bb0335 article-title: The pharmacokinetics of water-in-oil-in-water-type multiple emulsion of a new tacrolimus formulation publication-title: Lipids contributor: fullname: Kazui – volume: 117 start-page: 14 year: 2017 end-page: 28 ident: bb0180 article-title: Cyclosporine a delivery to the eye: a comprehensive review of academic and industrial efforts publication-title: Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahrenstechnik EV contributor: fullname: Garrigue – volume: 30 start-page: 958 year: 2011 end-page: 961 ident: bb0155 article-title: Cyclosporine a 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis publication-title: Cornea contributor: fullname: Holsclaw – volume: 28 start-page: 153 year: 2012 end-page: 158 ident: bb0375 article-title: Ocular safety and pharmacokinetics study of FK506 suspension eye drops after corneal transplantation publication-title: J. Ocul. Pharmacol. Ther. contributor: fullname: Chen – volume: 26 start-page: 165 year: 2010 end-page: 174 ident: bb0235 article-title: A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis publication-title: J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther. contributor: fullname: Hayashi – volume: 6 year: 1997 ident: bb0360 article-title: The effect of mode of administration on medical outcomes study health ratings and EuroQol scores in AIDS publication-title: Qual. Life Res. contributor: fullname: Feinberg – volume: 2 start-page: 192 year: 2011 end-page: 194 ident: bb0175 article-title: Reduction in drop size of ophthalmic topical drop preparations and the impact of treatment publication-title: J. Adv. Pharm. Technol. Res. contributor: fullname: Goli – volume: 115 start-page: 763 year: 1993 end-page: 769 ident: bb0205 article-title: A clinical trial of FK506 in refractory uveitis publication-title: Am J. Ophthalmol. contributor: fullname: Inaba – volume: 43 start-page: 51 year: 1997 end-page: 58 ident: bb0260 article-title: Ultrapure poly(vinyl alcohol) hydrogels with mucoadhesive drug delivery characteristics publication-title: Eur. J. Pharm. Biopharm. contributor: fullname: Mongia – volume: 31 start-page: 945 year: 2012 end-page: 949 ident: bb0215 article-title: Clinical treatment of dry eye using 0.03% tacrolimus eye drops publication-title: Cornea contributor: fullname: Hida – volume: 18 start-page: 345 year: 2004 end-page: 351 ident: bb0035 article-title: Vernal keratoconjunctivitis publication-title: Eye contributor: fullname: Lambiase – volume: 15 start-page: 1275 year: 1998 end-page: 1280 ident: bb0290 article-title: Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an immortalized human corneal epithelial cell line publication-title: Pharm. Res. contributor: fullname: Urtti – volume: 74 start-page: 1002 year: 2017 end-page: 1006 ident: bb0080 article-title: Stability of tacrolimus ophthalmic solution publication-title: Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm. contributor: fullname: Alós-Almiñana – volume: 118 start-page: 723 year: 1994 end-page: 729 ident: bb0150 article-title: FK506 treatment of noninfectious uveitis publication-title: Am J. Ophthalmol. contributor: fullname: Tanaka – volume: 123 start-page: 769 year: 2007 end-page: 778 ident: bb0045 article-title: Real-time assessment of cytotoxicity by impedance measurement on a 96-well plate publication-title: Sensors Actuators B Chem. contributor: fullname: Rossi – volume: 63 start-page: S240 year: 2011 end-page: S252 ident: bb0135 article-title: Measures of adult pain: visual analog scale for pain (VAS pain), numeric rating scale for pain (NRS pain), McGill pain questionnaire (MPQ), short-form McGill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short Form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP) publication-title: Arthritis Care Res. contributor: fullname: French – year: 2011 ident: bb0220 article-title: Guide for the care and use of laboratory animals publication-title: The National Academies Collection: Reports funded by National Institutes of Health contributor: fullname: National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals – volume: 40 start-page: 352 year: 2016 end-page: 370 ident: bb0095 article-title: Evaluation of the in vitro ocular toxicity of the fortified antibiotic eye drops prepared at the hospital pharmacy departments publication-title: Farm. Hosp. Organo Of. Expresion Cient. Soc. Espanola Farm. Hosp contributor: fullname: Otero-Espinar – volume: 63 start-page: 547 year: 2011 end-page: 554 ident: bb0120 article-title: Molecular imaging with SPECT as a tool for drug development publication-title: Adv. Drug Deliv. Rev. contributor: fullname: Pauwels – volume: 13 start-page: 308 year: 2013 end-page: 314 ident: bb0340 article-title: Use of cyclosporine a and tacrolimus in treatment of vernal keratoconjunctivitis publication-title: Curr Allergy Asthma Rep contributor: fullname: Kosrirukvongs – volume: 66 start-page: 807 year: 1991 end-page: 815 ident: bb0190 article-title: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes publication-title: Cell contributor: fullname: Schreiber – year: 2017 ident: bb0355 publication-title: Pharmacologic Therapy of Ocular Disease, Handbook of Experimental Pharmacology – volume: 23 start-page: 135 year: 2016 ident: bb0005 article-title: Tacrolimus ointment for treatment of vernal keratoconjunctivitis publication-title: Middle East Afr. J. Ophthalmol. contributor: fullname: Al-Hakami – volume: 40 start-page: 1738 year: 1999 end-page: 1744 ident: bb0165 article-title: Characterization of cyclosporin a transport in cultured rabbit corneal epithelial cells: P-glycoprotein transport activity and binding to cyclophilin publication-title: Invest. Ophthalmol. Vis. Sci. contributor: fullname: Ota – volume: 495 start-page: 680 year: 2015 end-page: 691 ident: bb0085 article-title: Ocular safety comparison of non-steroidal anti-inflammatory eye drops used in pseudophakic cystoid macular edema prevention publication-title: Int. J. Pharm. contributor: fullname: Otero-Espinar – volume: 123 start-page: 425 year: 2016 end-page: 433 ident: bb0185 article-title: Long-term natural history of dry eye disease from the Patient's perspective publication-title: Ophthalmology contributor: fullname: Schaumberg – volume: 528 start-page: 714 year: 2017 end-page: 722 ident: bb0195 article-title: Cysteamine polysaccharide hydrogels: study of extended ocular delivery and biopermanence time by PET imaging publication-title: Int. J. Pharm. contributor: fullname: Fernández-Ferreiro – volume: 58 start-page: 772 year: 2017 end-page: 780 ident: bb0100 article-title: Positron emission tomography for the development and characterization of corneal permanence of ophthalmic pharmaceutical formulations publication-title: Invest. Ophthalmol. Vis. Sci. contributor: fullname: Aguiar – volume: 54 start-page: 3852 year: 2013 end-page: 3856 ident: bb0230 article-title: Analysis of ethanol effects on corneal epithelium publication-title: Invest. Ophthalmol. Vis. Sci. contributor: fullname: Ko – volume: 10 start-page: 643 year: 2016 end-page: 647 ident: bb0305 article-title: Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis publication-title: Clin. Ophthalmol. Auckl. NZ contributor: fullname: Tabbara – volume: 57 start-page: 87 year: 1999 end-page: 99 ident: bb0380 article-title: Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate publication-title: J. Control. Release Off. J. Control. Release Soc. contributor: fullname: Hashida – volume: 34 start-page: 2737 year: 1993 end-page: 2742 ident: bb0270 article-title: Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye publication-title: Invest. Ophthalmol. Vis. Sci. contributor: fullname: Nguyen – volume: 97 start-page: 1395 year: 2013 end-page: 1398 ident: bb0200 article-title: Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study publication-title: Br. J. Ophthalmol. contributor: fullname: Kwitko – volume: 75 start-page: 432 year: 2016 end-page: 437 ident: bb0275 article-title: Adherence assessment of eye drops in patients with glaucoma using 8 item Morisky score: a cross sectional study publication-title: Rev. Bras. Oftalmol. contributor: fullname: Barbosa – volume: 50 start-page: 612 year: 2012 end-page: 618 ident: bb0050 article-title: Evaluation of the cytotoxicity of cigarette smoke condensate by a cellular impedance biosensor publication-title: Food Chem. Toxicol. contributor: fullname: Hu – volume: 20 start-page: 995 year: 2006 end-page: 1004 ident: bb0365 article-title: Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity publication-title: Toxicol. in Vitro contributor: fullname: Xie – volume: 11 start-page: 288 year: 1992 end-page: 293 ident: bb0315 article-title: Ocular surface residence times of artificial tear solutions publication-title: Cornea contributor: fullname: Bron – volume: 98 start-page: 1023 year: 2014 end-page: 1027 ident: bb0105 article-title: Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement publication-title: Br. J. Ophthalmol. contributor: fullname: Miyazaki – volume: 19 start-page: 400 year: 2014 end-page: 412 ident: bb0010 article-title: In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations publication-title: Drug Discov. Today contributor: fullname: Lobo – start-page: 35 year: 2016 end-page: 51 ident: bb0030 article-title: Allergic Diseases of the Eye contributor: fullname: Bielory – year: 1994 ident: bb0280 article-title: The Pharmaceutical Codex: Principles and Practice of Pharmaceutics, Twelfth contributor: fullname: Royal Pharmaceutical Society of Great Britain Dept of Pharmaceutical – volume: 61 start-page: 275 year: 2012 end-page: 282 ident: bb0070 article-title: Blood level of tacrolimus in patients with severe allergic conjunctivitis treated by 0.1% Tacrolimus ophthalmic suspension publication-title: Allergol. Int. contributor: fullname: Miyazaki – volume: 91 start-page: 51 year: 2007 end-page: 55 ident: bb0160 article-title: Tacrolimus immunosuppression in high-risk corneal grafts publication-title: Br. J. Ophthalmol. contributor: fullname: Dua – volume: 10 start-page: 795 year: 2005 end-page: 805 ident: bb0015 article-title: Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays publication-title: J. Biomol. Screen. contributor: fullname: Abassi – volume: 141 start-page: 28 year: 2016 end-page: 35 ident: bb0390 article-title: Hyaluronic acid-coated niosomes facilitate tacrolimus ocular delivery: Mucoadhesion, precorneal retention, aqueous humor pharmacokinetics, and transcorneal permeability publication-title: Colloids Surf. B: Biointerfaces contributor: fullname: Xu – year: 1996 ident: bb0145 contributor: fullname: International Conference on Harmonisation (ICH) – volume: 92 start-page: 108 year: 2008 end-page: 111 ident: bb0210 article-title: Fluorophotometric measurement of the precorneal residence time of topically applied hyaluronic acid publication-title: Br. J. Ophthalmol. contributor: fullname: Nishida – volume: 1950 start-page: 2374 year: 1991 end-page: 2381 ident: bb0255 article-title: FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells publication-title: J. Immunol. Baltim. Md contributor: fullname: Marone – volume: 4 year: 2017 ident: bb0300 article-title: Topical tacrolimus in anterior segment inflammatory disorders publication-title: Eye Vis. contributor: fullname: Shoughy – volume: 240 start-page: 137 year: 2002 end-page: 143 ident: bb0225 article-title: Suppression of experimental immune-mediated blepharoconjunctivitis in Brown Norway rats by topical application of FK506 publication-title: Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. contributor: fullname: Ueno – volume: 135 start-page: 574 year: 1999 end-page: 580 ident: bb0285 article-title: Tacrolimus: the drug for the turn of the millennium? publication-title: Arch. Dermatol. contributor: fullname: Homey – volume: 25 start-page: 872 year: 2011 end-page: 880 ident: bb0170 article-title: Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis publication-title: Eye (Lond.) contributor: fullname: Behrouz – volume: 2 start-page: 47 year: 2013 end-page: 64 ident: bb0250 article-title: Ocular drug delivery systems: An overview publication-title: World J. Pharmacol. contributor: fullname: Mitra – volume: 36 start-page: 408 year: 2013 end-page: 413 ident: bb0110 article-title: Galenic and analytic development of tacrolimus 0.06% eye drops publication-title: J. Fr. Ophtalmol. contributor: fullname: Delbosc – start-page: 379 year: 2016 end-page: 384 ident: bb0125 article-title: Tacrolimus publication-title: SpringerLink contributor: fullname: Dick – volume: 78 start-page: 295 year: 2015 end-page: 299 ident: bb0240 article-title: Comparison of 1% cyclosporine eye drops in olive oil and in linseed oil to treat experimentally-induced keratoconjunctivitis sicca in rabbits publication-title: Arq. Bras. Oftalmol. contributor: fullname: Andrade – volume: 48 start-page: 5000 year: 2007 end-page: 5006 ident: bb0295 article-title: Benefits and side effects of different vegetable oil vectors on apoptosis, oxidative stress, and P2X7 cell death receptor activation publication-title: Invest. Ophthalmol. Vis. Sci. contributor: fullname: Rat – volume: 117 start-page: 14 year: 2017 ident: 10.1016/j.ejps.2018.04.038_bb0180 article-title: Cyclosporine a delivery to the eye: a comprehensive review of academic and industrial efforts publication-title: Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahrenstechnik EV doi: 10.1016/j.ejpb.2017.03.006 contributor: fullname: Lallemand – volume: 66 start-page: 807 year: 1991 ident: 10.1016/j.ejps.2018.04.038_bb0190 article-title: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes publication-title: Cell doi: 10.1016/0092-8674(91)90124-H contributor: fullname: Liu – volume: 17 start-page: 932 year: 2011 ident: 10.1016/j.ejps.2018.04.038_bb0345 article-title: Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis publication-title: Mol. Vis. contributor: fullname: Wakamatsu – volume: 1950 start-page: 2374 issue: 146 year: 1991 ident: 10.1016/j.ejps.2018.04.038_bb0255 article-title: FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells publication-title: J. Immunol. Baltim. Md contributor: fullname: de Paulis – volume: 45 start-page: 221 year: 2010 ident: 10.1016/j.ejps.2018.04.038_bb0350 article-title: Determination of tacrolimus ophthalmic emulsion by HPLC publication-title: J. Chin. Pharm. Sci. contributor: fullname: Wan – start-page: 35 year: 2016 ident: 10.1016/j.ejps.2018.04.038_bb0030 contributor: fullname: Bielory – volume: 93 start-page: 173 year: 2001 ident: 10.1016/j.ejps.2018.04.038_bb0140 article-title: The faces pain scale – revised: toward a common metric in pediatric pain measurement publication-title: Pain doi: 10.1016/S0304-3959(01)00314-1 contributor: fullname: Hicks – volume: 115 start-page: 763 year: 1993 ident: 10.1016/j.ejps.2018.04.038_bb0205 article-title: A clinical trial of FK506 in refractory uveitis publication-title: Am J. Ophthalmol. doi: 10.1016/S0002-9394(14)73645-1 contributor: fullname: Mochizuki – volume: 0 start-page: 1 year: 2017 ident: 10.1016/j.ejps.2018.04.038_bb0115 article-title: Roles of IL-6 in ocular inflammation: a review publication-title: Ocul. Immunol. Inflamm. contributor: fullname: Ghasemi – volume: 48 start-page: 5000 year: 2007 ident: 10.1016/j.ejps.2018.04.038_bb0295 article-title: Benefits and side effects of different vegetable oil vectors on apoptosis, oxidative stress, and P2X7 cell death receptor activation publication-title: Invest. Ophthalmol. Vis. Sci. doi: 10.1167/iovs.07-0229 contributor: fullname: Said – volume: 13 start-page: 308 year: 2013 ident: 10.1016/j.ejps.2018.04.038_bb0340 article-title: Use of cyclosporine a and tacrolimus in treatment of vernal keratoconjunctivitis publication-title: Curr Allergy Asthma Rep doi: 10.1007/s11882-013-0345-0 contributor: fullname: Vichyanond – volume: 74 start-page: 1002 year: 2017 ident: 10.1016/j.ejps.2018.04.038_bb0080 article-title: Stability of tacrolimus ophthalmic solution publication-title: Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm. doi: 10.2146/ajhp160169 contributor: fullname: Ezquer-Garin – volume: 118 start-page: 723 year: 1994 ident: 10.1016/j.ejps.2018.04.038_bb0150 article-title: FK506 treatment of noninfectious uveitis publication-title: Am J. Ophthalmol. doi: 10.1016/S0002-9394(14)72551-6 contributor: fullname: Ishioka – volume: 32 start-page: 543 year: 1997 ident: 10.1016/j.ejps.2018.04.038_bb0335 article-title: The pharmacokinetics of water-in-oil-in-water-type multiple emulsion of a new tacrolimus formulation publication-title: Lipids doi: 10.1007/s11745-997-0069-1 contributor: fullname: Uno – volume: 36 start-page: 675 year: 2017 ident: 10.1016/j.ejps.2018.04.038_bb0385 article-title: Comparative evaluation of Tacrolimus versus interferon alpha-2b eye drops in the treatment of vernal Keratoconjunctivitis: a randomized, double-masked study publication-title: Cornea doi: 10.1097/ICO.0000000000001200 contributor: fullname: Zanjani – volume: 75 start-page: 432 year: 2016 ident: 10.1016/j.ejps.2018.04.038_bb0275 article-title: Adherence assessment of eye drops in patients with glaucoma using 8 item Morisky score: a cross sectional study publication-title: Rev. Bras. Oftalmol. doi: 10.5935/0034-7280.20160087 contributor: fullname: Ribeiro – volume: 50 start-page: 612 year: 2012 ident: 10.1016/j.ejps.2018.04.038_bb0050 article-title: Evaluation of the cytotoxicity of cigarette smoke condensate by a cellular impedance biosensor publication-title: Food Chem. Toxicol. doi: 10.1016/j.fct.2011.11.040 contributor: fullname: Chen – volume: 31 start-page: 945 year: 2012 ident: 10.1016/j.ejps.2018.04.038_bb0215 article-title: Clinical treatment of dry eye using 0.03% tacrolimus eye drops publication-title: Cornea doi: 10.1097/ICO.0b013e31823f8c9b contributor: fullname: Moscovici – volume: 108 start-page: 1838 year: 2001 ident: 10.1016/j.ejps.2018.04.038_bb0310 article-title: Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts publication-title: Ophthalmology doi: 10.1016/S0161-6420(01)00759-X contributor: fullname: Sloper – year: 2011 ident: 10.1016/j.ejps.2018.04.038_bb0220 article-title: Guide for the care and use of laboratory animals contributor: fullname: National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals – volume: 135 start-page: 574 year: 1999 ident: 10.1016/j.ejps.2018.04.038_bb0285 article-title: Tacrolimus: the drug for the turn of the millennium? publication-title: Arch. Dermatol. doi: 10.1001/archderm.135.5.574 contributor: fullname: Ruzicka – volume: 141 start-page: 28 year: 2016 ident: 10.1016/j.ejps.2018.04.038_bb0390 article-title: Hyaluronic acid-coated niosomes facilitate tacrolimus ocular delivery: Mucoadhesion, precorneal retention, aqueous humor pharmacokinetics, and transcorneal permeability publication-title: Colloids Surf. B: Biointerfaces doi: 10.1016/j.colsurfb.2016.01.014 contributor: fullname: Zeng – volume: 30 start-page: 958 year: 2011 ident: 10.1016/j.ejps.2018.04.038_bb0155 article-title: Cyclosporine a 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis publication-title: Cornea doi: 10.1097/ICO.0b013e31820cd607 contributor: fullname: Jeng – volume: 40 start-page: 352 year: 2016 ident: 10.1016/j.ejps.2018.04.038_bb0095 article-title: Evaluation of the in vitro ocular toxicity of the fortified antibiotic eye drops prepared at the hospital pharmacy departments contributor: fullname: Fernández-Ferreiro – volume: 10 start-page: 887 year: 2016 ident: 10.1016/j.ejps.2018.04.038_bb0320 article-title: The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye publication-title: Clin. Ophthalmol. Auckl. NZ doi: 10.2147/OPTH.S101627 contributor: fullname: Stonecipher – volume: 113 start-page: S178 year: 2004 ident: 10.1016/j.ejps.2018.04.038_bb0065 article-title: Vernal keratoconjunctivitis publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2004.01.077 contributor: fullname: Dumrongkigchaiporn – volume: 61 start-page: 275 year: 2012 ident: 10.1016/j.ejps.2018.04.038_bb0070 article-title: Blood level of tacrolimus in patients with severe allergic conjunctivitis treated by 0.1% Tacrolimus ophthalmic suspension publication-title: Allergol. Int. doi: 10.2332/allergolint.11-OA-0349 contributor: fullname: Ebihara – volume: 15 start-page: 1275 year: 1998 ident: 10.1016/j.ejps.2018.04.038_bb0290 article-title: Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an immortalized human corneal epithelial cell line publication-title: Pharm. Res. doi: 10.1023/A:1011956327987 contributor: fullname: Saarinen-Savolainen – ident: 10.1016/j.ejps.2018.04.038_bb0325 contributor: fullname: The Association for Research in Vision and Ophthalmology – year: 2017 ident: 10.1016/j.ejps.2018.04.038_bb0355 – volume: 41 start-page: 890 year: 2016 ident: 10.1016/j.ejps.2018.04.038_bb0245 article-title: Evaluation of the ocular tolerance of three Tacrolimus topical pharmaceutical preparations by bovine corneal opacity and permeability test publication-title: Curr. Eye Res. doi: 10.3109/02713683.2015.1082187 contributor: fullname: Pastor-Clerigues – start-page: 51 year: 2017 ident: 10.1016/j.ejps.2018.04.038_bb0055 article-title: Ocular manifestations of allergic and immunologic diseases publication-title: SpringerLink contributor: fullname: Christensen – volume: 19 start-page: 400 year: 2014 ident: 10.1016/j.ejps.2018.04.038_bb0010 article-title: In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2013.10.001 contributor: fullname: Almeida – volume: 25 start-page: 872 year: 2011 ident: 10.1016/j.ejps.2018.04.038_bb0170 article-title: Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis publication-title: Eye (Lond.) doi: 10.1038/eye.2011.75 contributor: fullname: Kheirkhah – volume: 123 start-page: 425 year: 2016 ident: 10.1016/j.ejps.2018.04.038_bb0185 article-title: Long-term natural history of dry eye disease from the Patient's perspective publication-title: Ophthalmology doi: 10.1016/j.ophtha.2015.10.011 contributor: fullname: Lienert – volume: 57 start-page: 87 year: 1999 ident: 10.1016/j.ejps.2018.04.038_bb0380 article-title: Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate publication-title: J. Control. Release Off. J. Control. Release Soc. doi: 10.1016/S0168-3659(98)00150-3 contributor: fullname: Yura – volume: 36 start-page: 553 year: 2008 ident: 10.1016/j.ejps.2018.04.038_bb0025 article-title: Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells publication-title: Clin. Exp. Ophthalmol. doi: 10.1111/j.1442-9071.2008.01803.x contributor: fullname: Ayaki – volume: 63 start-page: 547 year: 2011 ident: 10.1016/j.ejps.2018.04.038_bb0120 article-title: Molecular imaging with SPECT as a tool for drug development publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2010.09.015 contributor: fullname: Gomes – volume: 8 start-page: 1039 year: 1991 ident: 10.1016/j.ejps.2018.04.038_bb0060 article-title: Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions publication-title: Pharm. Res. doi: 10.1023/A:1015813225804 contributor: fullname: Davies – volume: 78 start-page: 295 year: 2015 ident: 10.1016/j.ejps.2018.04.038_bb0240 article-title: Comparison of 1% cyclosporine eye drops in olive oil and in linseed oil to treat experimentally-induced keratoconjunctivitis sicca in rabbits publication-title: Arq. Bras. Oftalmol. doi: 10.5935/0004-2749.20150078 contributor: fullname: Parrilha – volume: 23 start-page: 135 year: 2016 ident: 10.1016/j.ejps.2018.04.038_bb0005 article-title: Tacrolimus ointment for treatment of vernal keratoconjunctivitis publication-title: Middle East Afr. J. Ophthalmol. doi: 10.4103/0974-9233.164616 contributor: fullname: Al-Amri – year: 1994 ident: 10.1016/j.ejps.2018.04.038_bb0280 contributor: fullname: Royal Pharmaceutical Society of Great Britain Dept of Pharmaceutical – volume: 11 start-page: 288 year: 1992 ident: 10.1016/j.ejps.2018.04.038_bb0315 article-title: Ocular surface residence times of artificial tear solutions publication-title: Cornea doi: 10.1097/00003226-199207000-00003 contributor: fullname: Snibson – volume: 528 start-page: 714 year: 2017 ident: 10.1016/j.ejps.2018.04.038_bb0195 article-title: Cysteamine polysaccharide hydrogels: study of extended ocular delivery and biopermanence time by PET imaging publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2017.06.060 contributor: fullname: Luaces-Rodríguez – volume: 33 start-page: 545 year: 2008 ident: 10.1016/j.ejps.2018.04.038_bb0020 article-title: Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study publication-title: Curr. Eye Res. doi: 10.1080/02713680802149115 contributor: fullname: Attas-Fox – start-page: 379 year: 2016 ident: 10.1016/j.ejps.2018.04.038_bb0125 article-title: Tacrolimus publication-title: SpringerLink contributor: fullname: Greiner – volume: 12 start-page: 1279 year: 2016 ident: 10.1016/j.ejps.2018.04.038_bb0040 article-title: Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK) publication-title: Expert Opin. Drug Metab. Toxicol. doi: 10.1080/17425255.2016.1209481 contributor: fullname: Bonniard – volume: 24 start-page: 19 year: 2017 ident: 10.1016/j.ejps.2018.04.038_bb0130 article-title: Preparation of tacrolimus ophthalmic solution using cyclodextrins publication-title: J. Birjand Univ. Med. Sci. contributor: fullname: Hajiahmadi – volume: 2 start-page: 47 year: 2013 ident: 10.1016/j.ejps.2018.04.038_bb0250 article-title: Ocular drug delivery systems: An overview publication-title: World J. Pharmacol. doi: 10.5497/wjp.v2.i2.47 contributor: fullname: Patel – volume: 91 start-page: 51 year: 2007 ident: 10.1016/j.ejps.2018.04.038_bb0160 article-title: Tacrolimus immunosuppression in high-risk corneal grafts publication-title: Br. J. Ophthalmol. doi: 10.1136/bjo.2006.097428 contributor: fullname: Joseph – volume: 36 start-page: 408 year: 2013 ident: 10.1016/j.ejps.2018.04.038_bb0110 article-title: Galenic and analytic development of tacrolimus 0.06% eye drops publication-title: J. Fr. Ophtalmol. doi: 10.1016/j.jfo.2012.03.019 contributor: fullname: Gauthier – volume: 58 start-page: 772 year: 2017 ident: 10.1016/j.ejps.2018.04.038_bb0100 article-title: Positron emission tomography for the development and characterization of corneal permanence of ophthalmic pharmaceutical formulations publication-title: Invest. Ophthalmol. Vis. Sci. contributor: fullname: Fernández-Ferreiro – volume: 26 start-page: 165 year: 2010 ident: 10.1016/j.ejps.2018.04.038_bb0235 article-title: A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis publication-title: J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther. doi: 10.1089/jop.2009.0087 contributor: fullname: Ohashi – volume: 495 start-page: 680 year: 2015 ident: 10.1016/j.ejps.2018.04.038_bb0085 article-title: Ocular safety comparison of non-steroidal anti-inflammatory eye drops used in pseudophakic cystoid macular edema prevention publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2015.09.058 contributor: fullname: Fernández-Ferreiro – volume: 495 start-page: 680 year: 2015 ident: 10.1016/j.ejps.2018.04.038_bb0090 article-title: Ocular safety comparison of non-steroidal anti-inflammatory eye drops used in pseudophakic cystoid macular edema prevention publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2015.09.058 contributor: fullname: Fernández-Ferreiro – volume: 40 start-page: 1738 year: 1999 ident: 10.1016/j.ejps.2018.04.038_bb0165 article-title: Characterization of cyclosporin a transport in cultured rabbit corneal epithelial cells: P-glycoprotein transport activity and binding to cyclophilin publication-title: Invest. Ophthalmol. Vis. Sci. contributor: fullname: Kawazu – volume: 63 start-page: S240 year: 2011 ident: 10.1016/j.ejps.2018.04.038_bb0135 publication-title: Arthritis Care Res. doi: 10.1002/acr.20543 contributor: fullname: Hawker – volume: 43 start-page: 51 year: 1997 ident: 10.1016/j.ejps.2018.04.038_bb0260 article-title: Ultrapure poly(vinyl alcohol) hydrogels with mucoadhesive drug delivery characteristics publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/S0939-6411(96)00010-0 contributor: fullname: Peppas – volume: 98 start-page: 1023 year: 2014 ident: 10.1016/j.ejps.2018.04.038_bb0105 article-title: Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement publication-title: Br. J. Ophthalmol. doi: 10.1136/bjophthalmol-2013-304453 contributor: fullname: Fukushima – volume: 25 start-page: 345 year: 2009 ident: 10.1016/j.ejps.2018.04.038_bb0370 article-title: Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration publication-title: J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther. doi: 10.1089/jop.2008.0125 contributor: fullname: Yuan – volume: 240 start-page: 137 year: 2002 ident: 10.1016/j.ejps.2018.04.038_bb0225 article-title: Suppression of experimental immune-mediated blepharoconjunctivitis in Brown Norway rats by topical application of FK506 publication-title: Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. doi: 10.1007/s00417-001-0424-0 contributor: fullname: Nishino – volume: 20 start-page: 995 year: 2006 ident: 10.1016/j.ejps.2018.04.038_bb0365 article-title: Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity publication-title: Toxicol. in Vitro doi: 10.1016/j.tiv.2005.12.008 contributor: fullname: Xing – volume: 56 start-page: 4324 year: 2015 ident: 10.1016/j.ejps.2018.04.038_bb0330 article-title: Barriers to follow-up and strategies to improve adherence to appointments for care of chronic eye diseases publication-title: Investig. Opthalmology Vis. Sci. doi: 10.1167/iovs.15-16444 contributor: fullname: Thompson – volume: 28 start-page: 153 year: 2012 ident: 10.1016/j.ejps.2018.04.038_bb0375 article-title: Ocular safety and pharmacokinetics study of FK506 suspension eye drops after corneal transplantation publication-title: J. Ocul. Pharmacol. Ther. doi: 10.1089/jop.2011.0108 contributor: fullname: Yuan – volume: 123 start-page: 769 year: 2007 ident: 10.1016/j.ejps.2018.04.038_bb0045 article-title: Real-time assessment of cytotoxicity by impedance measurement on a 96-well plate publication-title: Sensors Actuators B Chem. doi: 10.1016/j.snb.2006.10.024 contributor: fullname: Ceriotti – volume: 34 start-page: 2737 year: 1993 ident: 10.1016/j.ejps.2018.04.038_bb0270 article-title: Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye publication-title: Invest. Ophthalmol. Vis. Sci. contributor: fullname: Pleyer – volume: 6 year: 1997 ident: 10.1016/j.ejps.2018.04.038_bb0360 article-title: The effect of mode of administration on medical outcomes study health ratings and EuroQol scores in AIDS publication-title: Qual. Life Res. contributor: fullname: Wu – ident: 10.1016/j.ejps.2018.04.038_bb0145 contributor: fullname: International Conference on Harmonisation (ICH) – volume: 2 start-page: 192 year: 2011 ident: 10.1016/j.ejps.2018.04.038_bb0175 article-title: Reduction in drop size of ophthalmic topical drop preparations and the impact of treatment publication-title: J. Adv. Pharm. Technol. Res. doi: 10.4103/2231-4040.85540 contributor: fullname: Kumar – ident: 10.1016/j.ejps.2018.04.038_bb0265 – volume: 99 start-page: 306 year: 2010 ident: 10.1016/j.ejps.2018.04.038_bb0395 article-title: PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft excel publication-title: Comput. Methods Prog. Biomed. doi: 10.1016/j.cmpb.2010.01.007 contributor: fullname: Zhang – volume: 10 start-page: 795 year: 2005 ident: 10.1016/j.ejps.2018.04.038_bb0015 article-title: Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays publication-title: J. Biomol. Screen. doi: 10.1177/1087057105279635 contributor: fullname: Atienza – volume: 18 start-page: 345 year: 2004 ident: 10.1016/j.ejps.2018.04.038_bb0035 article-title: Vernal keratoconjunctivitis publication-title: Eye doi: 10.1038/sj.eye.6700675 contributor: fullname: Bonini – volume: 92 start-page: 108 year: 2008 ident: 10.1016/j.ejps.2018.04.038_bb0210 article-title: Fluorophotometric measurement of the precorneal residence time of topically applied hyaluronic acid publication-title: Br. J. Ophthalmol. doi: 10.1136/bjo.2007.121533 contributor: fullname: Mochizuki – volume: 54 start-page: 3852 year: 2013 ident: 10.1016/j.ejps.2018.04.038_bb0230 article-title: Analysis of ethanol effects on corneal epithelium publication-title: Invest. Ophthalmol. Vis. Sci. doi: 10.1167/iovs.13-11717 contributor: fullname: Oh – volume: 4 year: 2017 ident: 10.1016/j.ejps.2018.04.038_bb0300 article-title: Topical tacrolimus in anterior segment inflammatory disorders publication-title: Eye Vis. doi: 10.1186/s40662-017-0072-z contributor: fullname: Shoughy – volume: 15 start-page: 517 year: 2015 ident: 10.1016/j.ejps.2018.04.038_bb0075 article-title: Ocular inflammatory diseases: molecular pathogenesis and immunotherapy publication-title: Curr. Mol. Med. doi: 10.2174/1566524015666150731095426 contributor: fullname: Egwuagu – volume: 10 start-page: 643 year: 2016 ident: 10.1016/j.ejps.2018.04.038_bb0305 article-title: Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis publication-title: Clin. Ophthalmol. Auckl. NZ doi: 10.2147/OPTH.S99157 contributor: fullname: Shoughy – volume: 97 start-page: 1395 year: 2013 ident: 10.1016/j.ejps.2018.04.038_bb0200 article-title: Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study publication-title: Br. J. Ophthalmol. doi: 10.1136/bjophthalmol-2013-303639 contributor: fullname: Magalhaes |
SSID | ssj0006870 |
Score | 2.3824034 |
Snippet | Severe allergic ocular diseases as atopic keratoconjunctivitis can induce corneal damage due to inflammatory substances released from giant papillae.... |
SourceID | crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 152 |
SubjectTerms | Administration, Ophthalmic Adolescent Adult Animals Cell Survival - drug effects Child Cornea - drug effects Cornea - metabolism Corneal residence time Cytotoxicity Drug Compounding Drug Contamination Drug Stability Effectiveness Epithelium, Corneal - drug effects Epithelium, Corneal - metabolism Eye Diseases - diagnosis Eye Diseases - drug therapy Eye Diseases - metabolism Eye drops Female Humans Hyaluronic Acid - chemistry Hydrogen-Ion Concentration Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - chemistry Immunosuppressive Agents - metabolism Immunosuppressive Agents - toxicity Male Ophthalmic Solutions Osmolar Concentration Pharmaceutical Vehicles - chemistry Pilot Projects Polyvinyl Alcohol - chemistry Positron-Emission Tomography Pregnancy Prospective Studies Rats, Sprague-Dawley Stability Tacrolimus Tacrolimus - administration & dosage Tacrolimus - chemistry Tacrolimus - metabolism Tacrolimus - toxicity Treatment Outcome Young Adult |
Title | Preclinical characterization and clinical evaluation of tacrolimus eye drops |
URI | https://dx.doi.org/10.1016/j.ejps.2018.04.038 https://www.ncbi.nlm.nih.gov/pubmed/29705214 |
Volume | 120 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b8IwELYQXbpUfb-Rh4qlpDix4zgjQkX0hZAKEptlO44EUkMEYWDpb6-dB2kXho5JnMT57Nydrfu-A-BB4pCxkEVOqHzkmJBaOVKj2CEqElRJQvx8w-1jRIdT8jrzZw3Qr7gwNq2ytP2FTc-tdXmmW6LZTefz7icKPYbMktm1ElYIW8VPYpyRmdNP33WaB2V5wTjb2LGtS-JMkeOlF6mV7HZZLndqOSp7ndMvzzM4BkdlyAh7Ra9OQEMnp6A9LjSntx04qSlU6w5sw3GtRr09A-9j830l_RGqnTxzwb6EIong7mqt_A2XMcyEshV9vjZrqLcaRqtluj4H08HzpD90yhIKjsI-zRwcYgO5IIQEnqCu9CKzJDW_YUzjUGClXVeyQLOAoUihyARTglAtJVOxJla6DF-AZrJM9BWAPo2xL0w4GGNNqBvJUGvlBlhRTxEsyTV4rLDjaaGUwasUsgW3SHOLNEeEG6SvgV_By_-MNzemfO99l8VY7N7hhYElIJObfz7xFhzao3y_Ft2BZrba6HsTaGSylc-kFjjovbwNRz-ChtK_ |
link.rule.ids | 315,786,790,4521,24144,27957,27958,45620,45714 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b8IwED5RGNql6rv06aFiKRFO7DjOiFARlIeQChKbFTuOBFIB8Rj497WTAO3C0DWOnfizfT5b930H8CZJyHnIYydUPnaMS60cqXHiUBVHTElK_fTCrddnrRH9HPvjAjR2XBgbVpnb_symp9Y6f1LL0awtJpPaFw49js2R2bUSVpiQEyiZll1ahFK93Wn19waZ8TRnnH3fsRVy7kwW5qWnC6va7fJU8dTSVI7uT782n-YFnOdeI6pnP3YJBT27gsogk53eVtHwwKJaVVEFDQ6C1Ntr6A5MF3MGJFJ7heaMgImiWYz2pQfxbzRP0DpSNqnP92aF9FajeDlfrG5g1PwYNlpOnkXBUcRna4eExKAeUUoDL2Ku9GJzKjUrMWFJGBGlXVfyQPOA41jh2PhTEWVaSq4STa16GbmF4mw-0_eAfJYQPzIeYUI0ZW4sQ62VGxDFPEWJpGV432EnFplYhthFkU2FRVpYpAWmwiBdBn8Hr_gz5MJY86P17rKx2H_DCwPLQaYP_2zxFU5bw15XdNv9ziOc2ZL0-hY_QXG93Ohn43es5Us-r34A1lPVdQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preclinical+characterization+and+clinical+evaluation+of+tacrolimus+eye+drops&rft.jtitle=European+journal+of+pharmaceutical+sciences&rft.au=Luaces-Rodr%C3%ADguez%2C+Andrea&rft.au=Touri%C3%B1o-Peralba%2C+Rosario&rft.au=Alonso-Rodr%C3%ADguez%2C+Iria&rft.au=Garc%C3%ADa-Otero%2C+Xurxo&rft.date=2018-07-30&rft.eissn=1879-0720&rft.volume=120&rft.spage=152&rft_id=info:doi/10.1016%2Fj.ejps.2018.04.038&rft_id=info%3Apmid%2F29705214&rft.externalDocID=29705214 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0928-0987&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0928-0987&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0928-0987&client=summon |